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ABSTRACT 
Hennekam lymphangiectasia–lymphedema syndrome is an autosomal recessive disorder, with 
25% of patients having mutations in CCBE1. We identified a family with two brothers 
presenting with primary lymphedema, and performed exome sequencing to determine the cause 
of their disease. Analysis of four family members showed that both affected brothers had the 
same rare compound heterozygous mutations in CCBE1. The presumed paternally inherited 
NM_133459.3:c.310G>A; p.(Asp104Asn), lies adjacent to other known pathogenic CCBE1 
mutations, while the maternally inherited NM_133459.3:c.80T>C; p.(Leu27Pro) lies in the 
CCBE1 signal peptide, which has not previously been associated with disease.  Functional 
analysis in a zebrafish model of lymphatic disease showed that both mutations lead to CCBE1 
loss of function, confirming the pathogenicity of these variants and expanding the genotypic 
spectrum of lymphatic disorders. 
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INTRODUCTION 
Hennekam lymphangiectasia–lymphedema syndrome is characterized by generalized 
lymphatic dysplasia with malformations of the lymphatic system affecting various organs, 
including the intestinal tract, pericardium, and limbs. Facial dysmorphism and cognitive 
impairment are also features commonly associated with disease presentation [Hennekam et al., 
1989]. Hennekam syndrome is a genetically heterogeneous disorder. Biallelic mutations in 
CCBE1 (Hennekam lymphangiectasia-lymphedema syndrome 1 (HKLLS1; MIM:235510)) and 
FAT4 (Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2; MIM:616006)) have 
been reported as causative, with approximately 25% of patients having mutations in CCBE1 
[Alders et al., 2014]. Collagen- and calcium-binding EGF domain-containing protein 1 
(CCBE1) is indispensible for lymphangiogenesis during development in humans and model 
organisms. Hogan et al [2009a] identified a causative coding mutation in ccbe1 using a forward 
genetic screen in zebrafish. The mutant, termed full of fluid (fof), lacked truncal lymphatic 
vessels including the thoracic duct, but retained normal blood vasculature.  
The CCBE1 mutations previously reported to be causative for HKLLS1 are 
predominantly missense mutations located in the protein functional domains (collagen domain 
or EGF domain) or cysteine rich regions upstream of the EGF domain [Alders et al., 2013]. Here 
we report two brothers suffering from a primary lymphedema with a clinical presentation 
consistent with Hennekam lymphangiectasia-lymphedema syndrome, in whom exome 
sequencing (ES) identified bi-allelic damaging variants in CCBE1.  
CLINICAL REPORT 
The family was referred when their second son presented with a protein-losing 
enteropathy. The parents were non-consanguineous and there was a healthy older brother. The 
Crawford	et	al.	 	 	 2	
proband was born by a vaginal delivery at 41 weeks weighing 4,440 g. He presented at 2 weeks 
of age. He had hypoalbuminemia at 3 weeks of age and some dysmorphic features.  The finding 
of asymmetrical variable edema of both hands and feet after normalization of his serum albumin 
supported a diagnosis of intestinal lymphangiectasia.  His younger brother was also affected by 
the condition. He was delivered at 38 weeks gestation after a pregnancy complicated by 
polyhydramnios. His birth weight was 3,320 g and he was noted to have an undescended testis 
and pedal edema. He was admitted to hospital at day 10 with hypoalbuminemia associated with 
diarrhea and poor feeding.  He was noted to have gastro-intestinal reflux. He was assumed to 
have the same diagnosis as his brother. He also had problems with upper airway obstruction. He 
had variable inspiratory and expiratory stridor from birth. Bronchoscopy demonstrated the 
presence of tracheobronchomalacia. The first affected boy had no intellectual problems, 
however the second boy had developmental delay, a sensory processing disorder and had some 
seizures. Both brothers presented with similar facial features. Each had round faces with widely 
spaced eyes. They had depressed nasal bridges with bilateral epicanthus, long philtrums and thin 
upper vermilion. The features were consistent with a diagnosis of Hennekam syndrome.  
METHODS 
This study was approved by the Royal Brisbane and Women’s Hospital Human Research 
Ethics Committee, the Royal Children’s Hospital Human Research Ethics Committee and the 
University of Queensland Medical Research Ethics Committee. Informed consent was obtained 
from the three siblings and their mother prior to initiation of this study. Peripheral blood was 
collected from all individuals and genomic DNA extracted using standard procedures.  
DNA library preparation, exome enrichment, sequencing, read alignment and variant 
calling were all performed as described [Simons et al., 2015]. Subsequent analysis and 
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identification of candidate variants was performed with an in-house workflow incorporating the 
annotated variant data and pedigree information. Targeted exons were sequenced to an average 
depth of at least 100X in all four family members. 
Intronic primers generating amplicons spanning exons 1 and 4 of CCBE1 were bi-
directionally Sanger sequenced to respectively identify, and confirm identified, variants with 
reads aligned to the reference human genome (GRCh37).  
The coding sequence of human CCBE1 was cloned into the pCS2+ vector and site 
directed mutagenesis performed to introduce p.Leu27Pro and p.Asp104Asn variants. Capped 
CCBE1 wildtype and variant mRNA were transcribed and 350 pg was injected into the yolk of 
single cell stage embryos as described [Hogan et al., 2009b].  The ccbe1 morpholino was 
injected as described [Hogan et al., 2009a].  Thoracic duct formation was quantified as present 
or absent in each body segment (somite) across six segments at 5 days post fertilization (dpf). 
For simplicity a score of thoracic duct present (TD+) or thoracic duct deficient (TD-) was 
determined based on the presence or complete absence of TD fragments, respectively.  Live 
zebrafish embryos were mounted in 0.5% low melting agarose laterally and imaged using a 
Zeiss LSM 710 FCS confocal microscope.  Images were processed using ImageJ 1.47 software 
(National Institute of Health).   
Primer sequences for Sanger sequencing, CCBE1 cloning and mutagenesis are available 
upon request. 
RESULTS 
Genomic DNA was provided for four family members, including the mother, two 
affected male children, and one unaffected male sibling. No paternal DNA sample was 
collected. 
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Both affected individuals shared the same two rare missense variants in CCBE1. Initial 
analysis of ES data identified a single potentially pathogenic variant in CCBE1, NM_133459.3: 
c.310G>A; p.(Asp104Asn), that occurs in a conserved residue in the cysteine rich region amino-
terminal to the EGF functional domain. This variant is present in dbSNP 142 (rs139165727) and 
is reported in ExAc as restricted to the European (Non- Finnish) population with an allele 
frequency of 0.0003 (with no homozygous individuals reported). It is predicted to be damaging 
by Polyphen and neutral by SIFT. The CCBE1 Asp104 residue is conserved, and is invariant in 
all sequenced vertebrates. Both affected siblings were heterozygous for the c.310G>A variant, 
as was the unaffected sibling. The mother was wild type at this position. The second variant was 
initially undetected by exome sequencing due to poor coverage of the 5’ end of the gene. Sanger 
sequencing was then conducted of exon 1 and identified the NM_133459.3: c.80T>C; 
p.(Leu27Pro) change. This variant was absent from both dbSNP 142 and ExAc. The CCBE1 
Leu27 residue is a conserved residue in the signal peptide sequence, a domain important for the 
extracellular secretion of the protein. This residue is invariant in all mammals and marsupials, 
with the p.(Leu27Pro) change predicted to be probably damaging by SIFT and Polyphen. The 
c.80T>C variant was inherited from the mother, was present in both affected brothers, and was 
not present in the unaffected sibling. The genotypes and the segregation of both CCBE1 variants 
were confirmed in all individuals by Sanger sequencing. The CCBE1 variants identified are 
consistent with bi allelic loss of function in CCBE1. 
To confirm that the two variants are deleterious to CCBE1 activity, we used a zebrafish 
model to perform a rescue assay for CCBE1 loss of function. The Asp104 residue is conserved 
between human and zebrafish, however there is considerable sequence divergence in the signal 
peptide at the site of the Leu27Pro variant (Figure 1).  For this reason, we used overexpression 
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of human CCBE1 mRNA for the rescue assay.  Zebrafish embryos were injected with either a 
previously validated morpholino (MO, modified anti-sense oligomer) targeting the zebrafish 
ccbe1 homologue alone [Hogan et al., 2009a; Alders et al., 2009], or the MO in conjunction 
with human CCBE1 mRNA.  
Injection of the ccbe1-targeting MO alone, resulted in the loss of lymphatic 
development. Co-injection of wild-type human CCBE1 mRNA with MO rescued the lymphatic 
defect in the majority of embryos tested. However, co-injection of either the p.Leu27Pro or 
p.Asp104Asn mutant CCBE1 mRNA failed to rescue lymphatic development in any embryo 
tested (Figure 2). These results demonstrate that both the Leu27Pro and Asp104Asn variants 
lead to loss of function of CCBE1. 
DISCUSSION 
Primary lymphedema is a chronic, genetically determined, heritable disorder of 
incorrectly developed vasculature that results in fluid (lymph) accumulation, particularly in the 
extremities. Mutations in nine genes have been identified in different forms of primary 
lymphedema, all of which appear to be involved in the vascular endothelial growth factor-
c/vascular endothelial growth factor receptor-3 signaling pathway [Alders et al., 2013; Mendola 
et al., 2013], a pathway shown to be essential for correct lymphatic vessel formation during 
embryonic development [Alitalo 2011].  
Of the various forms of primary lymphedema, CCBE1 mutations appear to be 
predominantly causative for Hennekam Syndrome [Alders et al., 2013]. Fewer than 50 patients 
with Hennekam Syndrome have been reported in the literature to date, with 25-29 % of those 
having biallelic CCBE1 coding mutations [Alders et al., 2014; Jackson et al., 2016] and 20% 
having biallelic FAT4 mutations. Fotiou et al [2015] recently reported biallelic mutations in 
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PIEZO1 can result in generalized lymphatic dysplasia, phenotypically similar to Hennekam 
Syndrome. 
The disease presentation in patients with Hennekam Syndrome is quite variable and, 
interestingly, does not appear to be indicative of the genotypic basis of the disorder [Alders et 
al., 2013]. Patients in whom pathogenic CCBE1 mutations are found are no exception, with 
Alders et al [2013] describing considerable phenotypic variation between individuals who had 
the same CCBE1 mutations. Here we present clinical reports for two affected brothers, both of 
whom had the same biallelic CCBE1 missense mutations, but also show phenotypic variation. In 
this family, the presentation of lymphedema and the facial dysmorphism characteristic of the 
disease was consistent between the boys, but the intellectual phenotype showed considerable 
intra-familial variation.  
Interestingly, neither of the mutations identified in the patients reported here were in 
functional domains, nor are they predicted to alter cysteine residues, and as such do not typify 
the CCBE1 mutations published to date. The p.(Asp104Asn) mutation we report here has 
previously been identified in conjunction with the common NM_133459.3:c.223T>A; 
p.(Cys75Ser) mutation in compound heterozygous siblings who presented with a mild 
phenotype [Connell et al., 2012], however this is the first report of a causative mutation in the 
signal peptide domain responsible for correct CCBE1 localization. 
To establish the deleterious nature of these mutations we employed a zebrafish 
lymphangiogenesis model that has been used for testing the pathogenicity of CCBE1 mutations 
identified in patients with HKLLS1 [Alders et al., 2009].  In this work, the authors assessed the 
pathogenicity of their CCBE1 mutations using the zebrafish equivalent of the human mutations.  
In the present study, as the Leu27 amino acid in the signal peptide is not conserved between 
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zebrafish and human, this prohibited the use of zebrafish mRNA for rescue experiments.  We 
therefore introduced the variants into human CCBE1 and used human CCBE1 mRNA to 
perform the rescue experiments.  The robust rescue we observed upon human CCBE1 mRNA 
injection into zebrafish ccbe1 MO embryos demonstrated that the human protein was functional 
in zebrafish and opens up new possibilities for using the zebrafish system for structural and 
functional assays as well as future therapeutic assays reliant upon using the human form of 
CCBE1. 
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FIGURE LEGENDS 
Figure 1: Schematic representation of the functional domains of CCBE1 (obtained from 
UniProt). The signal peptide (SP), calcium-binding EGF (Ca-EGF) domain, collagen repeat 1 
(coll-1), and collagen repeat 2 (coll-2) are indicated. Patient mutations and evolutionary 
conservation at those residues are depicted. 
 
Figure 2: Functional analyses of the human CCBE1 mutations in the ccbe1 zebrafish model 
using transgenic line TG(fli1a:gfp)y1, TG(kdr-l:ras-cherry)s916.  Fli1a (green) is expressed in 
both blood and lymphatic vessels, whereas kdr-l (red) is only expressed in blood vessels [Hogan 
et al., 2009a].  At 5 d post fertilization the thoracic duct (arrow) is present in a) control embryos, 
but is absent (*) in b) embryos injected with ccbe1 ATG-targeting morpholino.  The ccbe1 ATG 
MO phenotype is rescued by injection of c) wild-type human CCBE1 mRNA, but not with 
human mRNA encoding the d) p.Leu27Pro (L27P) or e) p.Asp104Asn (D104N) substitutions. f) 
Summary of rescue experiments evaluating the presence/absence of the thoracic duct (TD). 
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